April 4 (Reuters) – Amylyx Pharmaceuticals (AMLX.O), opens new tab will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from

Artificial intelligence has emerged as a double-edged sword for pharmaceutical companies, helping to develop new cures while also creating obstacles to obtaining drug patents potentially

PLYMOUTH, Minn.–(BUSINESS WIRE)–SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for epidural